Presentation is loading. Please wait.

Presentation is loading. Please wait.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

Published byAmie Perry Modified over 5 years ago

Similar presentations

Presentation on theme: "Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision."— Presentation transcript:

1 Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study.
Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Both MACEs in the very low risk group were coronary stenoses identified on an outpatient basis that did not require intervention. AMI, acute myocardial infarction; MACE, major adverse cardiac events. Richard Body et al. Heart 2014;100: Copyright © BMJ Publishing Group Ltd & British Cardiovascular Society. All rights reserved.

Download ppt "Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision."

Similar presentations

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
MACE rate among CAD severity groups (total 0

MACE rate among CAD severity groups (total 0
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.
Figure 2 Absolute difference in seasonal peak

Figure 2 Absolute difference in seasonal peak
Scanning Electron Microscope (SEM) images of the dialysis membranes: cross-section (a) 6 kDa, no polyvinylpyrrolidone (PVP); (b) 12 kDa, 2% PVP; (c) 16 kDa,

Scanning Electron Microscope (SEM) images of the dialysis membranes: cross-section (a) 6 kDa, no polyvinylpyrrolidone (PVP); (b) 12 kDa, 2% PVP; (c) 16 kDa,
Chart 3: Working example of oxygen section for hospital prescription charts (two panels are required on the prescription chart because oxygen may change.

Chart 3: Working example of oxygen section for hospital prescription charts (two panels are required on the prescription chart because oxygen may change.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Measure-specific reasons for exclusion (2010-Q4–2013-Q3).

Measure-specific reasons for exclusion (2010-Q4–2013-Q3).
(A) Meta-analysis of repeat revascularisation in randomised trials.

(A) Meta-analysis of repeat revascularisation in randomised trials.
Time course of changes in left ventricular ejection fraction (LVEF) and left ventricular diastolic dimension (LVDd) in 13 patients with the development.

Time course of changes in left ventricular ejection fraction (LVEF) and left ventricular diastolic dimension (LVDd) in 13 patients with the development.
(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.
Trends in relative risk of death before a mortality alert and after postalert 9-month lag period for (A) all diagnosis/procedure groups (for values 

Trends in relative risk of death before a mortality alert and after postalert 9-month lag period for (A) all diagnosis/procedure groups (for values 
Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)
Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.
Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.
Cardiovascular risk assessment in kidney transplantation

Cardiovascular risk assessment in kidney transplantation
Area under the receiver operating curve showing 0

Area under the receiver operating curve showing 0
Percentage of endometrial ablation procedures using balloon or microwave ablation procedures—National Institute for Health and Care Excellence guidance.

Percentage of endometrial ablation procedures using balloon or microwave ablation procedures—National Institute for Health and Care Excellence guidance.

Similar presentations

Ads by Google